Abstract | PURPOSE: METHODS: RESULTS: The mean duration of grade 4 neutropenia for the 3.6 mg pegteograstim (n = 33) was similar to that for the 6.0 mg pegteograstim (n = 26) (1.97 ± 1.79 days vs. 1.54 ± 0.95 days, p = 0.33). The 6.0 mg pegteograstim was selected to be compared with the 6.0 mg pegfilgrastim in the phase III part. In the phase III part, the primary analysis revealed that the efficacy of pegteograstim (n = 56) was non-inferior to that of pegfilgrastim (n = 59) [duration of grade 4 neutropenia, 1.64 ± 1.18 days vs. 1.80 ± 1.05 days; difference, -0.15 ± 1.11 (p = 0.36, 97.5 % confidence intervals = 0.57 and 0.26)]. The time to the absolute neutrophil count (ANC) recovery of pegteograstim (≥2000/μL) was significantly shorter than that of pegfilgrastim (8.85 ± 1.45 days vs. 9.83 ± 1.20 days, p < 0.0001). Other secondary endpoints showed no significant difference between the two groups. The safety profiles of the two groups did not differ significantly. CONCLUSIONS:
|
Authors | Ki Hyeong Lee, Ji-Yeon Kim, Moon Hee Lee, Hye Sook Han, Joo Han Lim, Keon Uk Park, In Hae Park, Eun Kyung Cho, So Young Yoon, Jee Hyun Kim, In Sil Choi, Jae Hoo Park, Young Jin Choi, Hee-Jun Kim, Kyung Hae Jung, Si-Young Kim, Do-Youn Oh, Seock-Ah Im |
Journal | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
(Support Care Cancer)
Vol. 24
Issue 4
Pg. 1709-17
(Apr 2016)
ISSN: 1433-7339 [Electronic] Germany |
PMID | 26423618
(Publication Type: Clinical Trial, Phase II, Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Recombinant Proteins
- Granulocyte Colony-Stimulating Factor
- pegfilgrastim
- Polyethylene Glycols
- pegylated granulocyte colony-stimulating factor
- Filgrastim
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects)
- Breast Neoplasms
(drug therapy)
- Female
- Filgrastim
- Granulocyte Colony-Stimulating Factor
(administration & dosage, therapeutic use)
- Humans
- Induction Chemotherapy
(methods)
- Maximum Tolerated Dose
- Middle Aged
- Neutropenia
(chemically induced)
- Polyethylene Glycols
(administration & dosage, therapeutic use)
- Recombinant Proteins
(administration & dosage, therapeutic use)
|